Evogene Shifts Focus to AI Drug Discovery Platform ‘ChemPass’ – Seeking to Secure Future Growth Engine

On February 25, 2026, Evogene has refocused its business strategy on its AI-driven drug discovery platform, ChemPass, signaling a shift towards leveraging artificial intelligence for new drug development. This strategic decision is viewed as a crucial step towards overcoming limitations of its previous business model and securing future growth engines. The investment community anticipates this shift will significantly bolster Evogene’s long-term viability.

Evogene’s Strategic Shift: Focused Investment in the ChemPass Platform

This strategic decision by Evogene reflects a deep understanding of the rapidly evolving trends in the pharmaceutical industry. Traditional drug development methods are costly and time-consuming, while leveraging AI technology can maximize efficiency across the entire process, from identifying candidate compounds to designing clinical trials and predicting drug efficacy. According to Investing.com, Evogene aims to realize the potential of AI-driven drug development through the ChemPass platform.

The Potential of AI-Driven Drug Development

AI excels at analyzing vast amounts of data and identifying patterns. This allows for increasing the likelihood of success in the early stages of drug development and significantly reducing development time and costs. Specifically, the ChemPass platform focuses on effectively utilizing this AI technology to maximize the efficiency of drug development.

Key Features of the ChemPass Platform

• Data Analysis and Prediction: ChemPass analyzes vast amounts of biological data, genomic information, and clinical data to identify potential drug candidates.


• Virtual Drug Design: Utilizing AI algorithms to design drug molecular structures and predict drug efficacy and safety.


• Clinical Trial Optimization: Optimizing clinical trial plans using AI-based simulations and increasing the likelihood of success.

Market Outlook and Future Strategy

The market for AI-driven drug development is growing rapidly, and Evogene’s shift represents a strategic choice to capitalize on this growth potential. According to FireMarkets’ market analysis, the use of AI in drug development is expected to be a key driver of the future pharmaceutical industry. Evogene is expected to secure a competitive advantage through the ChemPass platform and establish a foundation for continued growth.